Skip to content
Catalyst

inosineFinding

Inosine increases progression-free survival

raisesModerate evidenceFinding

01 · The sentence it was drawn from

“Compared with the control group, the 6‐ and 12‐month PFS rates were significantly higher in the inosine group (Table 2).”
Quoted verbatim from Inosine enhances the efficacy of immune-checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study.
This finding among the 3 findings on its endpoint

inosine

Progression-free survival

raises

Who
Adults aged 18-75 with advanced (locally advanced, recurrent, metastatic or unresectable) malignant solid tumours receiving PD-1/PD-L1 inhibitor therapy, with or without targeted therapy or chemotherapy, in both arms; PFS rates at the 6- and 12-month landmarks
Dose studied
inosine tablets, 0.2 g three times daily, added to PD-1/PD-L1 inhibitor regimen until progression or unacceptable toxicity

Moderate evidencePMID 39267574 · 2024

02 · The study

Study
RCT
Duration
not reported

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M7GGMBKVJDAYZEHE4AYRZGBN